Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich, Switzerland) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientists who discovered novel molecular mechanisms that can be exploited to prevent the development of non-genetic resistance to cancer therapies.

Florian Vogl is Chief Medical Officer at TOLREMO. He is a physician-scientist with deep expertise in oncology drug development and clinical strategy. Florian has held senior roles across the biotech and pharmaceutical sectors, including positions of increasing responsibility at Novartis, Amgen, Rainier Therapeutics, Cellestia Biotech, and Immutep Ltd. He earned his M.D. and Ph.D. in clinical pharmacology from the University of Munich and completed a postdoctoral fellowship at the International Agency for Research on Cancer.

Jessica Corson joined Tolremo in 2023 as our Chief Business Officer. Jessica has over 20 years of strategic and operational experience within the biotech industry. Most recently, she was Vice President of Corporate Strategy, Business Development and Alliance Management at Mirati Therapeutics, where she oversaw and executed the company’s strategy for external collaborations. Prior to joining Mirati in 2013, Jessica held roles of increasing responsibility in Business Development at Amylin Pharmaceuticals, from 2006 until the company’s sale to Bristol-Myers Squibb in 2012. Jessica serves on the board of directors at RS Oncology, a clinical-stage biotech company. She holds an M.B.A. from the UCLA Anderson School of Management and a B.S. in Biology from the University of California, San Diego.

Claudia Escher is Chief Operating Officer at TOLREMO. She joins from Biognosys, a Swiss company focusing on the development and application of mass spectrometry proteomics. As COO she was heading the contract research department and responsible for the commercial application of next generation proteomics for the pharmaceutical and biotechnology industry. Claudia graduated at the ETH Zürich in Environmental Sciences with a focus on biology. She holds a PhD in biochemistry from the University of Basel, Department of Neurobiology and the University of Applied Sciences Northwestern Switzerland for her work in biomarker discovery for muscular dystrophies using mass spectrometry.